3D Medicines (HKSE:01244) Payments of Debt: HK$-16.9 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01244 3D Medicines Inc HKSE:01244
46 GF Score
Price HK$2.65
GF Value HK$3.08
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is 3D Medicines Payments of Debt?

3D Medicines HKSE:01244 +7.29% 46 Payments of Debt is HK$-16.9 Mil as of Jun. 2026. GuruFocus rates HKSE:01244 with a GF Score™ of 46/100 and a GF Value™ of HK$3.08 (Modestly Undervalued). The stock has 5 warning signs investors should review.

3D Medicines's Payments of Debt for the six months ended in Jun. 2026 was HK$0.0 Mil.

3D Medicines's Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2026 was HK$-16.9 Mil.

3D Medicines Payments of Debt Related Terms

3D Medicines Payments of Debt Historical Data

* Premium members only.

The historical data trend for 3D Medicines's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

3D Medicines Payments of Debt Chart

3D Medicines Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial -250.29 151.06 102.96 -19.21 -96.91

3D Medicines Semi-Annual Data
Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Payments of Debt Get a 7-Day Free Trial -0.94 -18.28 -80.91 -16.92 0.00
HKSE:01244
46GF Score
3D Medicines Inc HKSE:01244
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

3D Medicines Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-16.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of HK$-16.9 Mil mean?
3D Medicines (HKSE:01244) has a Payments of Debt of HK$-16.9 Mil as of Jun. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on 3D Medicines and its competitors.
Is 3D Medicines' Payments of Debt too high?
3D Medicines' current Payments of Debt is HK$-16.9 Mil. Overall, 3D Medicines has a GF Score™ of 46/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does 3D Medicines' Payments of Debt compare to VRTX and REGN?
3D Medicines' Payments of Debt of HK$-16.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on 3D Medicines and its competitors. 3D Medicines's current Payments of Debt is HK$-16.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3D Medicines stock overvalued right now?
Based on GuruFocus' analysis, 3D Medicines (HKSE:01244) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$3.08, compared to a current price of HK$2.65 — trading 14% below its estimated fair value. The current Payments of Debt is HK$-16.9 Mil. 3D Medicines' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For 3D Medicines (HKSE:01244), the current Payments of Debt is HK$-16.9 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 3D Medicines (HKSE:01244) Overvalued in 2026?

Based on GuruFocus' analysis, 3D Medicines stock appears to be undervalued. The current stock price of HK$2.65 is trading 14% below its estimated GF Value™ of HK$3.08. GuruFocus considers 3D Medicines to be Modestly Undervalued.

Key valuation signals for HKSE:01244:

  • Payments of Debt: HK$-16.9 Mil
  • GF Value™: HK$3.08 vs. price of HK$2.65 (14% below fair value)
  • GF Score™: 46/100 with 5 warning signs

No single metric tells the full story. See the HKSE:01244 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

3D Medicines Business Description

Address No. 3 and No. 5, Laiyang Road, Shandong Province, Shinan District, Qingdao, CHN
3D Medicines Inc is an investment holding company. The company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products.It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life. It generates all of its revenue from China. Its commercialized product is Envita.
46GF Score

Get the complete analysis for HKSE:01244

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.65
Price
HK$3.08
GF Value